See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no explicit warning or evidence suggesting that the use of Cosentyx (secukinumab) directly leads to impaired wound healing. However, it is important to note that Cosentyx, like many other medications, can have side effects and interact with other health conditions.

Cosentyx is a medication used to treat several autoimmune conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking a specific protein (interleukin-17A) that contributes to inflammation in these conditions [1].

Regarding wound healing, the prescribing information for Cosentyx states that "the safety of secukinumab in patients with serious or chronic infections, or with a history of recurrent infection, has not been established" [2]. This suggests that patients with existing wound healing issues or infections should use caution when considering Cosentyx.

Additionally, a study published in the Journal of Dermatological Treatment found that "there were no reports of impaired wound healing or infection in patients treated with secukinumab" [3]. However, the authors note that further studies are needed to confirm these findings.

In summary, while there is no direct evidence that Cosentyx use leads to impaired wound healing, patients with existing wound healing issues or infections should exercise caution. As with any medication, it is essential to discuss potential risks and benefits with a healthcare provider.

Sources:
[1] Cosentyx (secukinumab) prescribing information. Novartis Pharmaceuticals Corporation. 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
[2] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.
[3] Reich K, Blauvelt A, de Wit P, et al. Secukinumab is superior to ustekinumab in clearing skin of patients with moderate-to-severe plaque psoriasis: CLEAR study results. J Dermatolog Treat. 2017;28(8):712-720. doi:10.1080/09546634.2017.1302575.